An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma

被引：0
|
作者：
Saiag, P. [1 ]
Robert, C. [2 ]
Grob, J. J. [3 ,4 ]
Mortier, L. [5 ]
Dereure, O. [6 ]
Lebbe, C. [7 ]
Mansard, S. [8 ]
Grange, F. [9 ]
Neidhardt, E-M. [10 ]
Lesimple, T. [11 ]
Machet, L. [12 ,13 ]
Bedane, C. [14 ]
Jeudy, G. [15 ]
Aubin, F. [16 ]
Dreno, B. [17 ]
Szenik, A. [18 ]
Denden, A. [18 ]
Dutriaux, C. [19 ]
机构：
[1] Ambroise Pare Hosp, AP HP, Dept Dermatol, Boulogne, France
[2] Inst Gustave Roussy, Dept Dermatol, Villejuif, France
[3] Aix Marseille Univ, Dept Dermatol, Marseille, France
[4] Univ Hosp Timone, APHM, Marseille, France
[5] Hop Claude Huriez, Dept Dermatol, Lille, France
[6] CHU Montpellier, Dept Dermatol, Montpellier, France
[7] Hop St Louis, Dept Dermatol Oncol, Paris, France
[8] CHU Estaing, Dept Dermatol, Clermont Ferrand, France
[9] Hosp Robert Debre, CHU Reims, Dept Dermatol, Reims, France
[10] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[11] Eugene Marquis Ctr, Dept Med Oncol, Rennes, France
[12] CHRU Tours, Dept Dermatol, Tours, France
[13] Univ Francois Rabelais Tours, Tours, France
[14] Hop Dupuytren, CHU Limoges, Dept Dermatol, Limoges, France
[15] Dijon Univ Hosp, Dept Dermatol, Dijon, France
[16] Besancon Univ Hosp, Dept Dermatol, EA3181, Besancon, France
[17] Ctr Hosp Univ Nantes, Dept Dermatol, Nantes, France
[18] Novartis Pharma France, Dept Med Oncol, Rueil Malmaison, France
[19] Hop St Andre, CHU Bordeaux, Dept Dermatol, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1260P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BOF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib
    Saiag, Philippe
    Robert, Caroline
    Grob, Jean -Jacques
    Mortier, Laurent
    Dereure, Olivier
    Lebbe, Celeste
    Mansard, Sandrine
    Grange, Florent
    Neidhardt, Eve-Marie
    Lesimple, Thierry
    Machet, Laurent
    Bedane, Christophe
    Maillard, Herve
    Dalac-Rat, Sophie
    Szenik, Alexandra
    Nardin, Charlee
    Denden, Amine
    Dutriaux, Caroline
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 57 - 65
  • [2] An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases
    Dutriaux, Caroline
    Robert, Caroline
    Grob, Jean-Jacques
    Mortier, Laurent
    Dereure, Olivier
    Lebbe, Celeste
    Mansard, Sandrine
    Grange, Florent
    Neidhardt, Eve-Marie
    Lesimple, Thierry
    Machet, Laurent
    Bedane, Christophe
    Maillard, Herve
    Dalac-Rat, Sophie
    Nardin, Charlee
    Szenik, Alexandra
    Denden, Amine
    Saiag, Philippe
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : 254 - 262
  • [3] Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma
    Dummer, Reinhard
    Long, Georgina V.
    Robert, Caroline
    Tawbi, Hussein A.
    Flaherty, Keith T.
    Ascierto, Paolo A.
    Nathan, Paul D.
    Rutkowski, Piotr
    Leonov, Oleg
    Dutriaux, Caroline
    Mandala, Mario
    Lorigan, Paul
    Ferrucci, Pier Francesco
    Grob, Jean Jacques
    Meyer, Nicolas
    Gogas, Helen
    Stroyakovskiy, Daniil
    Arance, Ana
    Brase, Jan C.
    Green, Steven
    Haas, Tomas
    Masood, Aisha
    Gasal, Eduard
    Ribas, Antoni
    Schadendorf, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (13) : 1428 - +
  • [4] An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis
    Dutriaux, C.
    Robert, C.
    Grob, J. J.
    Mortier, L.
    Dereure, O.
    Lebbe, C.
    Mansard, S.
    Grange, F.
    Neidhardt, E-M.
    Lesimple, T.
    Machet, L.
    Bedane, C.
    Maillard, H.
    Dalac-Rat, S.
    Nardin, C.
    Szenik, A.
    Denden, A.
    Saiag, P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma
    Si, Lu
    Zhang, Xiaoshi
    Shin, Sang Joon
    Fan, Yun
    Lin, Chia-Chi
    Kim, Tae Min
    Dechaphunkul, Arunee
    Maneechavakajorn, Jedzada
    Wong, Chi Sing
    Ilankumaran, Palanichamy
    Lee, Dung-Yang
    Gasal, Eduard
    Li, Haifu
    Guo, Jun
    EUROPEAN JOURNAL OF CANCER, 2020, 135 : 31 - 38
  • [6] COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma
    Berking, Carola
    Livingstone, Elisabeth
    Debus, Dirk
    Loquai, Carmen
    Weichenthal, Michael
    Leiter, Ulrike
    Kiecker, Felix
    Mohr, Peter
    Eigentler, Thomas K.
    Remy, Janina
    Schober, Katharina
    Heppt, Markus V.
    von Wasielewski, Imke
    Schadendorf, Dirk
    Gutzmer, Ralf
    CANCERS, 2023, 15 (18)
  • [7] An open-label phase 2a study of combination dabrafenib (D) and trametinib (T) in Asian patients (pts) with advanced BRAF V600-mutant acral lentiginous melanoma (ALM) or cutaneous melanoma (CM)
    Guo, J.
    Chang, W-C.
    Dechaphunkul, A.
    Fan, Y.
    Kim, T. M.
    Lin, C-C.
    Maneechavakajorn, J.
    Shin, S. J.
    Song, X.
    Cheng, S-T.
    Thongprasert, S.
    Wong, C. S.
    Wu, D.
    Zhang, X.
    Bettinger, S.
    Zhang, P.
    Mookerjee, B.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600-mutant unresectable or metastatic melanoma (MM).
    Long, Georgina V.
    Eroglu, Zeynep
    Infante, Jeffrey R.
    Patel, Sapna Pradyuman
    Daud, Adil
    Johnson, Douglas Buckner
    Gonzalez, Rene
    Kefford, Richard
    Hamid, Omid
    Schuchter, Lynn Mara
    Cebon, Jonathan S.
    Sharfman, William Howard
    McWilliams, Robert R.
    Sznol, Mario
    Weber, Jeffrey S.
    Mookerjee, Bijoyesh
    Gasal, Eduard
    Redhu, Suman
    Flaherty, Keith T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Chinese subgroup results from an open-label, phase IIa study of dabrafenib plus trametinib in Asian patients with advanced BRAF V600-mutant melanoma (NCT02083354)
    Mao, L.
    Wen, X.
    Xu, Y.
    Si, L.
    Zhang, X.
    Fan, Y.
    Guo, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S749 - S749
  • [10] Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
    Long, Georgina V.
    Weber, Jeffrey S.
    Infante, Jeffrey R.
    Kim, Kevin B.
    Daud, Adil
    Gonzalez, Rene
    Sosman, Jeffrey A.
    Hamid, Omid
    Schuchter, Lynn
    Cebon, Jonathan
    Kefford, Richard F.
    Lawrence, Donald
    Kudchadkar, Ragini
    Burris, Howard A., III
    Falchook, Gerald S.
    Algazi, Alain
    Lewis, Karl
    Puzanov, Igor
    Ibrahim, Nageatte
    Sun, Peng
    Cunningham, Elizabeth
    Kline, Amy S.
    Buono, HeatherDel
    OpattMcDowell, Diane
    Patel, Kiran
    Flaherty, Keith T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (08) : 871 - +
12345